Costs and consequences of immunosuppressive therapy in children with aplastic anemia

Haematologica

Volumn 96, Issue 6, 2011, Pages 793-795

  Shereck, Evan B ^a   Deyell, Rebecca J ^b   Kurre, Peter ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DANAZOL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; BONE MARROW DEPRESSION; CHILD; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EDITORIAL; ENGRAFTMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATHOPHYSIOLOGY; RECURRENCE RISK; SURVIVAL RATE; TREATMENT RESPONSE;

ANEMIA, APLASTIC; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79958063092     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044917     Document Type: Editorial

References (23)

1. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15(3):162-8.
2. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-8.
3. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3):101-22.
4. Kamio T, Ito E, Ohara A, Kosaka Y, Tsuchida M, Yagasaki H, et al. Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica. 2011;96(6):814-9.
5. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786-90.
6. Howard SC, Naidu PE, Hu XJ, Jeng MR, Rodriguez-Galindo C, Rieman MD, et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer. 2004;43(5):545-51.
7. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009;94(5):712-9.
8. Fuhrer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106(6):2102-4.
9. Deyell R, Shereck E, Milner R, Schultz K. Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia. Pediatric Hematology and Oncology. In press, 2011.
10. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814-9.
11. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726-35.
12. Fuhrer M. Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia. Bone Marrow Transplant. 2008;42 (Suppl 2):S97-100.
13. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12(12):1277-84.
14. Yagasaki H, Takahashi Y, Hama A, Kudo K, Nishio N, Muramatsu H, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant. 2010;45(10):1508-13.
15. Kobayashi R, Yabe H, Hara J, Morimoto A, Tsuchida M, Mugishima H, et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol. 2006; 135(5):693-6.
16. Jaime-Perez JC, Colunga-Pedraza PR, Gomez-Ramirez CD, Gutierrez- Aguirre CH, Cantu-Rodriguez OG, Tarin-Arzaga LC, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol. 2011;90(5):523-7.
17. Wang SC, Chen XJ, Zou Y, Yang WY, Liu TF, Zhang L, et al. [Prognostic factors of immunosuppressive therapy in children acquired aplastic anemia]. Zhonghua Er Ke Za Zhi. 2009;47(8):613-6.
18. Chuhjo T, Yamazaki H, Omine M, Nakao S. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am J Hematol. 2008;83(5):387-9.
19. Bacigalupo A, Chaple M, Hows J, Van Lint MT, McCann S, Milligan D, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA Working Party. Br J Haematol. 1993;83(1):145-51.
20. Risitano AM. Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. Br J Haematol. 2011;152(2):127-40.
21. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114(11): 2236-43.
22. Sanchez-Medal L, Gomez-Leal A, Duarte L, Guadalupe Rico M. Anabolic androgenic steroids in the treatment of acquired aplastic anemia. Blood. 1969;34(3):283-300.
23. Ehrlich P. Ueber einen Fall von Anaemie mit Bemerkungen ueber regenerative Veraenderungen des Knochenmarks. Charite Annalen. 1888(12):300.